DE60230388D1 - Mittel zur steurung der expression von il-12 - Google Patents
Mittel zur steurung der expression von il-12Info
- Publication number
- DE60230388D1 DE60230388D1 DE60230388T DE60230388T DE60230388D1 DE 60230388 D1 DE60230388 D1 DE 60230388D1 DE 60230388 T DE60230388 T DE 60230388T DE 60230388 T DE60230388 T DE 60230388T DE 60230388 D1 DE60230388 D1 DE 60230388D1
- Authority
- DE
- Germany
- Prior art keywords
- expression
- active ingredient
- hyaluronan
- interleukin
- enhancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hematology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001074078 | 2001-03-15 | ||
JP2001074077 | 2001-03-15 | ||
PCT/JP2002/002433 WO2002074318A1 (fr) | 2001-03-15 | 2002-03-14 | Agents de regulation d'expression d'il-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60230388D1 true DE60230388D1 (de) | 2009-01-29 |
Family
ID=26611324
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60230388T Expired - Lifetime DE60230388D1 (de) | 2001-03-15 | 2002-03-14 | Mittel zur steurung der expression von il-12 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20040097465A1 (de) |
EP (1) | EP1369119B1 (de) |
JP (1) | JP4234439B2 (de) |
AT (1) | ATE417617T1 (de) |
CA (1) | CA2440744C (de) |
DE (1) | DE60230388D1 (de) |
WO (1) | WO2002074318A1 (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4673217B2 (ja) * | 2003-04-23 | 2011-04-20 | 由紀夫 佐藤 | メチル化CpGポリヌクレオチド |
HUP0303779A2 (en) * | 2003-11-20 | 2006-02-28 | Richter Gedeon Vegyeszet | Pharmaceutical compositions containing hyaluronan complex for the treatment of sclerosis multiplex |
JP4889206B2 (ja) * | 2004-07-01 | 2012-03-07 | 有限会社 シーバイオン | Il−12産生誘導活性を有するマクロファージ活性化剤 |
JP4528898B2 (ja) * | 2004-07-26 | 2010-08-25 | 独立行政法人科学技術振興機構 | ケモカイン受容体ccr10の発現誘導剤 |
JP4576583B2 (ja) * | 2005-03-22 | 2010-11-10 | キユーピー株式会社 | ヒアルロン酸またはその塩、およびその製造方法、ならびにこれを含有する化粧料および食品組成物 |
US20070099867A1 (en) * | 2005-05-24 | 2007-05-03 | Glycoscience Laboratories, Inc. | Pharmaceutical agent containing hyaluronan as an active ingredient |
JP2009091248A (ja) * | 2006-01-17 | 2009-04-30 | Toshitsu Kagaku Kenkyusho:Kk | 外傷性神経障害および/または運動機能障害の治療薬 |
KR101482800B1 (ko) | 2006-02-24 | 2015-01-14 | 큐피가부시키가이샤 | 신규한 저분자량 히알루론산 및/또는 이의 염, 및 이를 이용한 화장료, 의약 조성물 및 식품 조성물 |
FR2908658B1 (fr) * | 2006-11-20 | 2011-11-11 | Centre Nat Rech Scient | Composition pour la prevention et/ou le traitement des maladies associees a la surexpression du tnf et/ou de l'il-12 |
US8153614B2 (en) | 2006-12-05 | 2012-04-10 | Glycoscience Laboratories, Inc. | Treatment of osteoarthritis |
JP2008266171A (ja) * | 2007-04-18 | 2008-11-06 | Q P Corp | 自己免疫疾患緩和剤ならびにこれを含有する医薬品および食品 |
SG188177A1 (en) | 2008-03-07 | 2013-03-28 | Acraf | Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
SG188178A1 (en) | 2008-03-07 | 2013-03-28 | Acraf | 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
WO2009113512A1 (ja) * | 2008-03-11 | 2009-09-17 | キユーピー株式会社 | Socs3発現促進剤、これを含有する医薬品および食品、ならびにsocs3の発現を促進する方法 |
JPWO2009113512A1 (ja) * | 2008-03-11 | 2011-07-21 | キユーピー株式会社 | Socs3発現促進剤、これを含有する医薬品および食品、ならびにsocs3の発現を促進する方法 |
FR2931480B1 (fr) * | 2008-05-23 | 2016-04-01 | Centre Nat Rech Scient | Analogues synthetiques de phosphatidyl-myo-inositol mannosides pourvus d'une active inhibitrice de la reponse inflammatoire |
US8462765B2 (en) * | 2008-08-20 | 2013-06-11 | Qualcomm Incorporated | Method and apparatus to perform ranging operations for wireless stations |
ES2665254T3 (es) | 2011-07-12 | 2018-04-25 | Holy Stone Healthcare Co., Ltd. | Composiciones que comprenden ácido hialurónico para tratamiento y prevención de enfermedades relacionadas con las mucosas |
US20150018305A1 (en) * | 2012-02-22 | 2015-01-15 | Hyaluronan Research Institute, Inc. | Sirtuin inducer, tissue repairing agent, hepatocyte growth factor inducer, tissue homeostasis maintenance agent, and tlr4 agonist, having hyaluronic acid fragment as active ingredient |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5095037B1 (en) * | 1989-12-21 | 1995-12-19 | Nissho Kk | Combined anti-inflammatory agent |
JP4010574B2 (ja) * | 1994-12-05 | 2007-11-21 | 電気化学工業株式会社 | 皮膚外用剤 |
EP0873128B1 (de) * | 1996-01-11 | 2004-11-17 | Jagotec Ag | Orale verabreichung wirksamer mengen von hyaluronsäure |
-
2002
- 2002-03-14 AT AT02705197T patent/ATE417617T1/de not_active IP Right Cessation
- 2002-03-14 DE DE60230388T patent/DE60230388D1/de not_active Expired - Lifetime
- 2002-03-14 WO PCT/JP2002/002433 patent/WO2002074318A1/ja active Application Filing
- 2002-03-14 US US10/471,824 patent/US20040097465A1/en not_active Abandoned
- 2002-03-14 EP EP02705197A patent/EP1369119B1/de not_active Expired - Lifetime
- 2002-03-14 CA CA002440744A patent/CA2440744C/en not_active Expired - Fee Related
- 2002-03-14 JP JP2002573025A patent/JP4234439B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP4234439B2 (ja) | 2009-03-04 |
CA2440744A1 (en) | 2002-09-26 |
EP1369119B1 (de) | 2008-12-17 |
WO2002074318A1 (fr) | 2002-09-26 |
EP1369119A1 (de) | 2003-12-10 |
US20040097465A1 (en) | 2004-05-20 |
ATE417617T1 (de) | 2009-01-15 |
CA2440744C (en) | 2009-12-08 |
JPWO2002074318A1 (ja) | 2004-07-08 |
EP1369119A4 (de) | 2004-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60230388D1 (de) | Mittel zur steurung der expression von il-12 | |
BR9908004A (pt) | Composto, composição e método para prevençãoou supressão de uma infecção viral | |
ITRM990338A0 (it) | Composizione dietetica o farmaceutica utile per la prevenzione o il trattamento dell'iperossaluria. | |
NO950297L (no) | Prolinamidderivater | |
ATE452640T1 (de) | Mittel für erkrankungen assoziert mit knochensubstanzverlust | |
DE69732170D1 (de) | Formulierung mit verzögerter Freisetzung enthaltend Kollagen und Glykosaminoglykan | |
DE60235083D1 (de) | Substituierte tetracyclin-verbindungen zur behandlung von malaria | |
MY141661A (en) | 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
WO2003053359A3 (en) | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders | |
DK1452524T3 (da) | "2-oxo-1-pyrrolidinderivat og dets farmaceutiske anvendelser" | |
EP1783126A3 (de) | N-Oxide von N-Phenyl-2-Pyrimidinamin Derivaten | |
AU2003211560A1 (en) | Novel phenylalanine derivative | |
ATE302616T1 (de) | Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe | |
HK1072181A1 (en) | Pharmaceutical compositions for the oral administration of heparin or derivatives thereof | |
DE50004334D1 (de) | Desodoriende zubereitungen enthaltend wasserlösliche -(1,3)-glucane | |
FI951856A0 (fi) | Farmaseuttinen koostumus osteoporoosin hoitamiseksi | |
ATE363267T1 (de) | Mittel zur verbesserung der hauttextur | |
DE69834500D1 (de) | Xanthinderivative zur behandlung von hirnischämie | |
NO20062857L (no) | Farmasoytisk preparat omfattende et sink-hyaluronatkompleks for behandling av multippel sklerose | |
DE60035429D1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
JP2002542281A5 (de) | ||
IL131216A (en) | Drugs inhibiting progress of pterygium and postoperative recurrence of the same | |
BR9904075A (pt) | Cetonas | |
MXPA05014143A (es) | Derivados de cumarina para el tratamiento de trastornos oftalmicos. | |
DK1352658T3 (da) | Forebyggelse eller lægemiddel mod endometriose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |